v3.26.1
FAIR VALUE MEASUREMENTS (Tables)
 6 Months Ended
Jun. 27, 2026
Fair Value Disclosures [Abstract]  
Schedule of Valuation of Financial Instruments Carried at Fair Value by the Applicable Pricing Categories
The table below summarizes the valuation of our financial instruments carried at fair value by the applicable pricing categories (in millions):
June 27, 2026December 31, 2025
Measured at fair value on a recurring basis:Level 1Level 2Level 3Level 1Level 2Level 3
Assets:
Foreign currency forward contracts$— $2.9 $— $— $2.4 $— 
Interest rate swap agreements— — — — 1.1 — 
Total assets$— $2.9 $— $— $3.5 $— 
Liabilities:
Foreign currency forward contracts$— $16.1 $— $— $14.5 $— 
Cross-currency swaps— 192.8 — — 265.6 — 
Interest rate swap agreements— 17.7 — — 32.8 — 
Total liabilities$— $226.6 $— $— $312.9 $— 
Measured at fair value on a non-recurring basis:
Assets:
Goodwill(1)
$— $— $107.1 $— $— $2,050.1 
Definite-lived intangible assets
— — — — — 5.5 
Equity method investments
— — — — — 3.5 
Total assets$— $— $107.1 $— $— $2,059.1 
(1) During the three months ended March 28, 2026, we assessed the fair value of our Women’s Health, Infant Formula, and Oral Care reporting units, resulting in residual goodwill of $107.1 million, $0, and $0, respectively. During the three months ended December 31, 2025, we assessed the fair value of our prior reporting units resulting in residual goodwill of $1,168.8 million and $881.3 million related to Consumer Self Care Americas and Consumer Self Care International, respectively.
Schedule of Fixed Rate Long-Term Debt
Our fixed rate long-term debt consisted of the following (in millions):
June 27, 2026December 31, 2025
Public BondsLevel 1Level 1
Carrying value (excluding discount)$2,257.8 $2,270.5 
Fair value$2,074.3 $2,149.8 
Schedule of Assumptions of Income and Market Approaches The key assumptions used in both the income and market approaches are summarized in the table below.
.
Reporting Unit
Discount Rate
Long-Term Growth Rate
GPCM Multiple
Women’s Health
14.0 %2.5 %
7.6x
Infant Formula
10.0 %2.5 %
n/a*
Oral Care
10.0 %2.5 %
8.0x
*The market approach was not considered applicable for the Infant Formula reporting unit.